AHA Statement on Most Favored Nation Model Interim Final Rule

Contact:

Colin Milligan, (202) 638-5491
Marie Johnson, (202) 626-2351

Tom Nickels
Executive Vice President
American Hospital Association

November 20, 2020

America’s hospitals and health systems have very deep concerns about the substance and legality of today’s Most Favored Nation Model interim final rule. Instead of holding drug companies accountable for drug prices, it slashes reimbursement to hospitals for drugs. In addition to the continued concerns we have expressed about the impact this model has on the 340B drug pricing program, we strongly question whether attempting to institute such a sweeping and controversial policy in an interim final rule is legally permissible.

By cutting drug reimbursements to hospitals — by an average of 65% when fully phased in — hospitals will have to absorb losses while drug companies are free to continue their trend of charging exorbitant prices. This will put hospitals in the terrible position of having to divert resources from other patient care simply to buy the drug therapies they need for their patients.

Cutting provider payments will not encourage companies to lower their prices. Drug companies will simply continue to try to maximize their profits.

It is alarming that the Administration has issued this operationally burdensome rule after over two years, in the middle of a pandemic with cases at record levels, and with less than six weeks’ notice before the model begins. Many of our nation's hospitals are already on the brink of being overwhelmed caring for surges of COVID-19 patients. We urge the Administration to withdraw this rule immediately and replace it with a serious effort at drug pricing reform.

###

Related Resources

Special Bulletin
Public
The Centers for Medicare & Medicaid Services (CMS) Nov. 20 released an interim final rule implementing the Most Favored Nation (MFN) Model, a new payment…
Letter/Comment
Public
The AHA on Friday sent a letter to the Health Resources and Services Administration’s Office of Pharmacy Affairs urging the agency to order drug manufacturers…
Letter/Comment
Public
In a letter to Senator Lamar Alexander and Representative Greg Walden, AHA expresses strong support for the 340B Drug Pricing Program.
Action Alert
Member
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary…
Action Alert
Member
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary…
Letter/Comment
Public
AHA follows up on our previous correspondence on the serious situation Eli Lilly, AstraZeneca and Sanofi are creating for the nation’s most vulnerable…